Tough comps and pricing pressure dampen growth during Q419
According to BioMedGPS’ SmartTRAK Financial Dashboard, the WW Trauma Market posted +2.8% growth, down from Q3, while the US achieved growth of +3.8%, also down from Q3. Trauma market leader DePuy Synthes (48.6% US Q4 share) reported while sales were down compared to Q319, gains were driven by overall market growth and strong adoption of their Femoral Neck System.
Tough comparisons, both YoY and sequentially, impacted the Q419 Trauma Market. The US pricing environment remains relatively steady as DePuy Synthes noted pricing pressure of -2.0%, in line with their Q2 and Q3 pricing (Q1 was -2.5%). Zimmer Biomet’s SET pricing improved in Q4 at -1.8% vs. Q3’s -2.0%. BioMedGPS believes 2019 pricing trended at -2.0 to -2.5%.
Among the many topics covered in the comprehensive Q419/FY19 Trauma Market Recap* are:
- Complete Market Breakdown and Highlights
- Tough Comps and Continued Pricing Pressure Influences the Trauma Market
- Lack of New Product Introductions Impacts Market
- Q419 Patent Activity Indicates Future Competition in Deformity Correction
- Trauma Regulatory Highlights
While companies touted IM Nailing and Plates & Screws as growth drivers for their trauma & extremities Q419 results, all were existing product lines that have gained traction. During the fourth quarter, a lack of new product introductions impacted the segment as did slightly tougher comps.
*The entire article can only be viewed by SmartTRAK subscribers to this module. For information on how to subscribe, please click the button below.
